Last reviewed · How we verify
The Effect of Dipyridamole on the Pharmacokinetics of Metformin (MetDipy)
The antihyperglycemic drug metformin and the thrombocyte aggregation inhibitor dipyridamole are often used concomitantly in patients with diabetes who have suffered a transient ischemic attack or stroke. It has recently been suggested that the gastrointestinal absorption of metformin is mediated by the equilibrative nucleoside transporter 4 (hENT4). Dipyridamole has been reported to inhibit hENT4 transport in vitro. The aim of this research proposal is to study the pharmacokinetic interaction between metformin and dipyridamole. The investigators hypothesize that dipyridamole reduces the gastrointestinal absorption of metformin. If this hypothesis can be confirmed, then the results of this study can explain in part the high variability in plasma metformin concentrations in patients treated with diabetes, and can be used to optimize pharmacotherapy in patients with diabetes.
Details
| Lead sponsor | Radboud University Medical Center |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 18 |
| Start date | 2012-04 |
| Completion | 2012-07 |
Conditions
- Diabetes
Interventions
- Metformin, dipyridamole
- Metformin
Primary outcomes
- The area under the curve of the metformin plasma concentration at several timepoints — 10 hours after ingestion of last dose of metformin
The area under the curve of the metformin plasma concentration at t=0, t=1, t=2, t=2.5, t=3, t=3.5, t=4, t=5, t=6, t=8, and t=10 hours after the intake and the Cmax. - Peak plasma concentration (Cmax) of metformin — about 3 hours after intake of last dose of metformin
Peak plasma concentration (Cmax) of metformin
Countries
Netherlands